Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles The Returns Gap Shows Investors Can't Stop Chasing Performance James Comtois Affinity, Janus Henderson Outpace Biopharma Peers in Tough Month Stephen Taub What Past Sector Concentrations Tell Us About Today's Tech-Heavy S&P 500 Sponsored by CME Group